2. Search Result
Search Result
Results for "

squalene synthase

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

5

Natural
Products

1

Recombinant Proteins

1

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-103087
    FIN56
    Maximum Cited Publications
    14 Publications Verification

    		 Ferroptosis Others
    FIN56 is a specific inducer of ferroptosis. FIN56 induces ferroptosis by inducing degradation of GPX4. FIN56 also binds to and activates squalene synthase .
    FIN56
  • HY-100313A
    YM-53601
    2 Publications Verification

    		 Farnesyl Transferase HCV Infection Metabolic Disease
    YM-53601, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 inhibits squalene synthase derived from human hepatoma cells with an IC50 of 79 nM. Lipid-lowering agent . YM-53601 is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .
    YM-53601
  • HY-16108A
    Squalene synthase-IN-3 tripotassium

    		Others Metabolic Disease
    Squalene synthase-IN-3 tripotassium (Compound 1) is a potent squalene synthase inhibitor .
    Squalene synthase-IN-3 tripotassium
  • HY-149405
    Squalene synthase-IN-1

    		Others Metabolic Disease
    Squalene synthase-IN-1 (compound 1) is a potent antihyperlipidemic agent acting through Squalene Synthase inhibition. Squalene synthase-IN-1 exhibits an outstanding antioxidant and anti-inflammatory activity. Squalene synthase-IN-1 displays a significant reduction not only of glucose but also of oxidative stress levels, while it did not cause any toxicity .
    Squalene synthase-IN-1
  • HY-163452
    Squalene synthase-IN-2

    		Others Metabolic Disease
    Squalene synthase-IN-2 (comppund isomer A-(1S, 3R)-14i) is an orally active squalene synthase inhibitor with IC50 values of 3.4, 99 nM for squalene synthase and cholesterol synthesis, respectively. Squalene synthase-IN-2 reduces plasma cholesterol and triglyceride .
    Squalene synthase-IN-2
  • HY-125311
    Zaragozic acid D

    		Farnesyl Transferase Cancer
    Zaragozic acid D is a squalene synthase inhibitor. Zaragozic acid D also is a farnesyl-protein transferase (FPTase) inhibitor with an IC50 value of 100 nM for bovine FPTase .
    Zaragozic acid D
  • HY-100313
    YM-53601 free base

    		Farnesyl Transferase HCV Metabolic Disease
    YM-53601 free base, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 free base inhibits squalene synthase derived from human hepatoma cells with an IC50 of 79 nM. Lipid-lowering agent . YM-53601 free base is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .
    YM-53601 free base
  • HY-B2097
    Incadronate disodium

    YM 175; Bisphonal

    		 Farnesyl Transferase Metabolic Disease
    Incadronate disodium (YM 175) is a bisphosphonate with strong inhibitory activity on bone resorption. Incadronate disodium indirectly stimulates renal 25-hydroxyvitamin D-1-hydroxylase by increasing circulating parathyroid hormone. Incadronate disodium, a cholesterol-lowering agent, is a potent inhibitor of rat liver microsomal squalene synthase (Ki=57 nM). Incadronate disodium inhibits sterol biosynthesis in mouse macrophage J774 cells (IC50=64 μM). Incadronate disodium has the potential for malignant tumors research .
    Incadronate disodium
  • HY-100299
    RPR107393 free base

    		Farnesyl Transferase Metabolic Disease
    RPR107393 free base is a selective squalene synthase inhibitor, which inhibits rat liver microsomal squalene synthase with an IC50 of 0.8 nM.
    RPR107393 free base
  • HY-123405
    YM-75440

    		Endogenous Metabolite Others
    YM-75440 is an orally active inhibitor of squalene synthase.
    YM-75440
  • HY-116290
    Zaragozic acid A
    1 Publications Verification

    Squalestatin S1

    		 Others Others
    Zaragozic acid A is a fungal metabolite that acts as a reversible competitive inhibitor of squalene synthase .
    Zaragozic acid A
  • HY-116290A
    Zaragozic acid A trisodium

    Squalestatin S1 trisodium

    		 Others Others
    Zaragozic acid A trisodium is a fungal metabolite that acts as a reversible competitive inhibitor of squalene synthase .
    Zaragozic acid A trisodium
  • HY-125324
    Squalestatin 3

    		Endogenous Metabolite Cardiovascular Disease
    Squalestatin 3 is a secondary metabolite, which can be isolated from Phoma. Squalestatin 3 is an inhibitor for squalene synthase with an IC50 of 6 nM .
    Squalestatin 3
  • HY-125439
    Squalestatin 2

    		Others Metabolic Disease
    Squalestatin 2 is a potent squalene synthase inhibitor. Squalestatin 2 has IC50 values of 5 and 4 nM in rat liver and tobacco, respectively .
    Squalestatin 2
  • HY-16274
    Lapaquistat acetate

    TAK-475

    		 Farnesyl Transferase Metabolic Disease
    Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene in the cholesterol biosynthesis pathway . Lapaquistat acetate is effective at lowering low-density lipoprotein cholesterol, but it might cause liver damage. Lapaquistat acetate is used for hypercholesterolemia and mevalonate kinase deficiency (MKD) research .
    Lapaquistat acetate
  • HY-135625
    BPH-1218

    		Parasite Infection
    BPH-1218 is an inhibitor of squalene synthase (SQS), with the IC50 of 31 nM and 64 nM for TcSQS and HsSQS, respectively, that can be used as an anti-infective agent .
    BPH-1218
  • HY-126871
    Zaragozic acid D2

    		Farnesyl Transferase Metabolic Disease Cancer
    Zaragozic acid D2 is the inhibitor for squalene synthase and Ras farnesyl-protein transferase (Ras FPTase), with IC50 of 2 nM and 100 nM, respectively. Zaragozic acid D2 is potentially ameliorating hypercholesterolemia and Ras-induced cancer .
    Zaragozic acid D2
  • HY-117807
    A-176120

    		Ras Cancer
    A-176120 is a potent inhibitor of farnesyltransferase, crucial for Ras protein farnesylation in cancer cells. It exhibits high selectivity for farnesyltransferase (IC50 1.2 ± 0.3 nM) over related enzymes like geranylgeranyltransferases and squalene synthase. Inhibition of Ras processing in H-ras and K-ras mutated cells demonstrates its efficacy in blocking Ras-mediated signaling. A-176120 shows anti-angiogenic effects by inhibiting vascular endothelial growth factor (VEGF) secretion and disrupting capillary formation in endothelial cells. In vivo studies reveal its ability to reduce tumor growth in Ras-transformed cells and enhance survival in animal models. These findings highlight A-176120 as a promising FPP analogue with potent anti-tumor and anti-angiogenic properties .
    A-176120

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: